Leukemia, Lymphoma
Conditions
Keywords
untreated childhood acute lymphoblastic leukemia, L1 childhood acute lymphoblastic leukemia, L2 childhood acute lymphoblastic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell childhood acute lymphoblastic leukemia, stage I childhood lymphoblastic lymphoma, stage II childhood lymphoblastic lymphoma, stage III childhood lymphoblastic lymphoma, stage IV childhood lymphoblastic lymphoma, Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia
Brief summary
RATIONALE: Collecting and storing samples of tumor tissue, blood, bone marrow, and other body fluids from patients to test in the laboratory and collecting information about the patient's health and treatment may help doctors learn more about cancer and help the study of cancer in the future. Studying these samples in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is collecting and looking at blood and tissue samples in children with newly diagnosed acute lymphoblastic leukemia.
Detailed description
OBJECTIVES: * Collect clinical data in parallel with biological data and samples from children with newly diagnosed acute lymphoblastic leukemia for biobanking, and use part of the biobanked material to perform specific translational projects to achieve objectives II-IV. * To identify new prognostic factors (e.g., minimal-residual disease \[MRD\] significance in small subgroups, miRNAs expression profile, PAX5 mutation, genetic abnormalities in T-cell acute lymphoblastic leukemia \[T-ALL\], and RAS pathway activation) and future therapeutic targets in children with newly diagnosed acute lymphoblastic leukemia. * To identify leukemia cell genetic alterations (e.g., mutations in T-ALL and miRNA expression in B-cell acute lymphoblastic leukemia \[B-ALL\]) and related molecular pathways (e.g., RAS pathway) underlying leukemogenesis. * To identify patient pharmacogenetic polymorphisms impacting individual response to corticosteroids as part of standard therapy and investigate their prognostic significance. OUTLINE: This is a prospective observational biobanking study. Patients undergo clinical evaluation, laboratory tests, and imaging periodically. Data are collected before, during, and after first-line standard therapy. Clinical data are collected from all patients in parallel with the biological data and samples. Biological samples are partly used to perform specific translational research (TR) projects. Remaining biological materials are stored for future research. The following TR projects are performed on the biological samples for this study. Biological samples are analyzed for allele-specific amplification of Ig/TCR clonal rearrangements to quantify minimal-residual disease (MRD) via real-time PCR (TR1 Project); miRNA expression via qPCR (TR 2 Project); the detection of main point mutations via high-resolution melting PCR (TR 3 Project); genetic polymorphisms via real-time TaqMan allelic-discrimination method (TR 4 Project); clinical significance of genetic abnormalities via quantitative real-time RT-PCR, direct sequencing, and fluorescence in situ hybridization (TR 5 Project); and RAS pathway activation via single-nucleotide polymorphism (SNP) analysis and gene-expression analysis (TR 6 Project).
Interventions
GENETICgene expression analysis
GENETICmutation analysis
GENETICpolymorphism analysis
OTHERbiologic sample preservation procedure
OTHERlaboratory biomarker analysis
OTHERpharmacogenomic studies
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
1 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Newly diagnosed acute lymphoblastic leukemia (ALL), meeting the following criteria: * FAB L1 or L2 morphology (any immunophenotype) and acute leukemias of ambiguous lineage (including biphenotypic or bilineal acute lymphoblastic leukemia) * Patients with mature B-cell acute lymphoblastic leukemia (B-ALL) (FAB L3 morphology and immunophenotypical mature B phenotype or B-ALL with documented presence of karyotype t(8;14), t(2;8) t(8;22) or breakpoints as in mature B-ALL) are excluded from this study * Patients must also meet the following criteria for participating in individual translational research (TR) project: * TR 1 project (MRD prognostic significance in small ALL subgroups): * All patients, categorized according to response to pre-phase (\< or \> 1,000 peripheral blasts/mm³ at day 8) and minimal-residual disease (MRD) level at end of the induction therapy * iAmp(21q) detected at presentation * Hypodiploidy detected at presentation by karyotype and/or fluorescence in situ hybridization (FISH) and/or DNA index * TR 2 project (miRNAs expression in pediatric ALL): * Initially, average-risk 1 (AR1) patients * In a second stage, the analysis might be extended to low-risk patients that still show treatment failure and high-risk ALL patients * TR 3 project (Prognostic value of newly described mutations in childhood B-ALL) * Initially, only B-cell precursor ALL patients * TR 4 project (Pharmacogenetics of the response to prephase and induction therapy): * All ALL patients * TR 5 project (Clinical significance of genetic abnormalities in childhood T-ALL) : * All patients with T-cell ALL, as defined by expression of T-cell surface antigens * TR 6 project (RAS pathway activation in childhood B-ALL): * All patients with B-lineage ALL * Patients with Philadelphia-chromosome positive ALL (documented presence of t(9;22)(q34;q11) and/or of the BCR/ABL fusion transcript) are eligible * Scheduled to receive therapy as per institutional standard practice and have not started therapy (except for a maximum of 7 days of systemic corticosteroids prior to diagnosis) * May only be registered to this study once PATIENT CHARACTERISTICS: * No psychological, familial, sociological, or geographical condition potentially hampering participation in the study protocol and follow-up schedule * Patients with Down syndrome are eligible PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival | — |
| Disease-free interval from complete remission | — |
| Response to pre-phase standard therapy | — |
| Adverse events to induction standard therapy | — |
| Overall survival | — |
| Biomarker levels | — |
Countries
Belgium, France, Portugal
Outcome results
None listed